NCT03126916
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Associated Conditions
Brain CancerSponsor
Children's Oncology Group
The overall goals of this study are to: Compare the effects, good and/or bad, of the experimental drug 131I-MIBG added to current COG recommended therapy to the effects of current COG recommended therapy without the experimental drug 131I-MIBG. Compare the effects, good and/or bad, of the experimental drug crizotinib added to current COG recommended therapy to the effects of current COG recommended therapy without the experimental drug crizotinib.
This study is currently enrolling.